Publicacions (26) Publicacions de Marta Larrayoz Ilundain

2023

  1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  2. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

  2. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

2020

  1. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial

    Leukemia, Vol. 34, Núm. 7, pp. 1760-1774

2019

  1. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: Results from 3 UK clinical trials

    Blood Advances, Vol. 3, Núm. 16, pp. 2474-2481

  2. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

    Haematologica, Vol. 104, Núm. 2, pp. 360-369

2018

  1. Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation

    Molecular and Cellular Proteomics, Vol. 17, Núm. 4, pp. 776-791

  2. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial

    Leukemia

  2. The dual Syk/JAK inhibitor cerdulatinib antagonizes b-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia

    Clinical Cancer Research, Vol. 23, Núm. 9, pp. 2313-2324

2016

  1. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors

    Haematologica, Vol. 101, Núm. 8, pp. 959-967

  2. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

    Leukemia, Vol. 30, Núm. 11, pp. 2179-2186

  3. IL-4 enhances expression and function of surface IgM in CLL cells

    Blood, Vol. 127, Núm. 24, pp. 3015-3025

  4. Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease

    Leukemia, Vol. 30, Núm. 6, pp. 1301-1310

  5. Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-PD-1 and anti-CD137 monoclonal antibodies

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. 524-536

  6. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL

    Blood, Vol. 128, Núm. 6, pp. 816-826

  7. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1

    Leukemia, Vol. 30, Núm. 2, pp. 351-360

2015

  1. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients

    PLoS ONE, Vol. 10, Núm. 4